<DOC>
	<DOCNO>NCT02333799</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability pharmacokinetics bedaquiline plus PA-824 plus linezolid 6 month treatment ( option 9 month subject remain culture positive month 4 ) Subjects either pulmonary extensively drug resistant tuberculosis ( XDR-TB ) , treatment intolerant non-responsive multi-drug resistant tuberculosis ( MDR-TB ) .</brief_summary>
	<brief_title>A Phase 3 Study Assessing Safety Efficacy Bedaquiline Plus PA-824 Plus Linezolid Subjects With Drug Resistant Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Inclusion Criteria 1 . Provide write , informed consent prior trialrelated procedure ( 18 , include consent legal guardian ) . 2 . Body weight ≥30 kg ( light clothing shoe ) . 3 . Willingness ability attend schedule followup visit undergo study assessment . 4 . Provide consent HIV testing ( HIV test perform within 1 month prior trial start , repeat long documentation provide [ ELISA and/or Western Blot ] ) . 5 . Male female , age 14 year . 6 . Subjects one follow pulmonary TB condition : 1 . XDRTB documented culture positive ( M.tb . ) result ( resistance isoniazid , rifamycins , fluoroquinolone injectable within 3 month prior screen ) ; 2 . MDRTB document culture positive result ( M.tb . ) within 3 month prior screen document nonresponse treatment best available regimen 6 month prior enrollment opinion Investigator adherent treatment adherent study regimen ; 3 . MDRTB document culture positive ( M.tb . ) result within 3 month prior screen unable continue second line drug regimen due document intolerance : i. PAS , ethionamide , aminoglycosides fluoroquinolones ; ii . Current treatment list render subject eligible study Investigator 's opinion . 7 . Chest XRay picture ( take within year prior screen ) consistent pulmonary TB opinion Investigator . 8 . Be nonchildbearing potential use effective method birth control , define : Nonchildbearing potential : 1 . Subject heterosexually active practice sexual abstinence ; 2 . Female Subject/sexual partner bilateral oophorectomy , bilateral tubal ligation and/or hysterectomy postmenopausal history menses least 12 consecutive month ; 3 . Male Subject/sexual partner vasectomise bilateral orchidectomy minimally three month prior Screening . Effective birth control method : A double contraceptive method use follow : 1 . Double barrier method include 2 follow : male condom , diaphragm , cervical cap , female condom ( male female condom use together ) ; 2 . Barrier method ( one ) combine hormonebased contraceptive intrauterine device female Subject/partner ; 3. willing continue practice birth control method throughout treatment 6 month ( male female Subjects ) last dose study medication discontinuation study medication case premature discontinuation . Note : Hormone base contraception alone may reliable take investigational medicinal product ; therefore , hormone base contraceptive alone use female Subjects female partner male Subjects prevent pregnancy . Exclusion Criteria Medical History 1 . Any condition Investigator 's opinion ( i.e. , unstable disease uncontrolled diabetes cardiomyopathy , extrapulmonary TB require extend treatment ) , participation trial would compromise wellbeing Subject prevent , limit confound protocol specify assessment . 2 . In judgment Investigator , patient expect survive 12 week . 3 . Karnofsky score &lt; 50 within 30 day prior entry . 4 . History allergy know hypersensitivity trial Investigational Medicinal Products related substance . 5 . HIV infected Subjects CD4+ count &lt; 50 cells/µL . For HIV infected Subjects CD4+ count ≥50 cells/µL ; . Currently treat need initiate antiretroviral therapy ( ART ) compatible allow ARTs consider appropriate candidate switch regimen ARVs allow . Examples allow treatment include limit follow . If question , discus Sponsor Medical Monitor confirmation appropriate ARV regimen . i. Nevirapine base regimen consist nevirapine combination NRTIs ; ii . Lopinavir/ritonavir ( Aluvia™ ) base regimen consist lopinavir/ritonavir ( Aluvia™ ) combination NRTIs ; iii . In case resistance intolerance two regimen , triple nucleosidase reverse trascriptase inhibitor ( NRTI ) base regimen consist zidovudine , lamivudine abacavir may use caution ; iv . Raltegravir combination nucleoside reverse transcriptase inhibitor ( NRTIs ) ; b . Can ensure 2 week interval commence IMP start ART , already ARTs . 6 . Having participate clinical study dose investigational agent within 8 week prior trial start currently enrol investigational study include treatment medicinal agent . Subjects participate observational study follow period trial include drug therapy may consider inclusion . 7 . Significant cardiac arrhythmia require medication . 8 . Subjects follow Screening : 1 . QTcF interval ECG &gt; 500 msec . Subjects QTcF &gt; 450 must discuss sponsor medical monitor enrolment . 2 . History additional risk factor Torsade de Pointes , ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ; 3 . Clinically significant ventricular arrhythmia ; 4 . Subjects cardiac abnormality may place risk arrhythmia must discuss sponsor medical monitor enrollment . Such abnormality include : Evidence ventricular preexcitation ( e.g. , Wolff Parkinson White syndrome ) ; Electrocardiographic evidence complete clinically significant incomplete leave bundle branch block right bundle branch block ; Evidence second third degree heart block ; Intraventricular conduction delay QRS duration 120 ms. 9 . Females positive pregnancy test Screening already know pregnant , breastfeeding , plan conceive child study within 6 month cessation treatment . Males plan conceive child study within 6 month cessation treatment . 10 . A peripheral neuropathy Grade 3 4 , accord DMID ( Appendix 2 ) . Or , subject Grade 1 2 neuropathy likely progress/worsen course study , opinion Investigator . Specific Treatments 11 . Concomitant use Monoamine Oxidase Inhibitors ( MAOIs ) prior use within 2 week treatment assignment . 12 . Concommitant use serotonergic antidepressant prior use within 3 day treatment assignment Investigator foresee potential risk serotonin syndrome combine linezolid . 13 . Concomitant use drug know prolong QTc interval ( include , limited , amiodarone , bepridil , chloroquine , chlorpromazine , cisapride , cyclobenzaprine , clarithromycin , disopyramide , dofetilide , domperidone , droperidol , erythromycin , fluoroquinolones , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , thioridazine ) . 14 . Concomitant use drug know induce myelosuppresion . 15 . Subjects may previously treat DS/MDRTB provide treatment is/was discontinue least 3 day prior treatment assignment . Based Laboratory Abnormalities 16 . Subjects follow toxicity Screening ( lab may repeat ) define enhanced Division Microbiology Infectious Disease ( DMID ) adult toxicity table ( November 2007 ) : 1. serum potassium less low limit normal laboratory ; 2 . Hemoglobin level &lt; 8.0 g/dL ; 3 . Platelet count &lt; 80,000/mm3 ; 4 . Absolute neutrophil count ( ANC ) &lt; 1000/ mm3 ; 5. aspartate aminotransferase ( AST ) ≥5.0 x ULN . Subjects AST &gt; 3.0 x ULN must discuss sponsor medical monitor enrolment ; 6. alanine aminotransferase ( ALT ) ≥5.0 x ULN . Subjects ALT &gt; 3.0 x ULN must discuss sponsor medical monitor enrolment ; 7. total bilirubin grade 3 great ( ≥2.0 x ULN , ≥1.50 x ULN accompany increase liver function test ) ; 8 . Serum creatinine level great 2 time upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>MDR-TB</keyword>
	<keyword>XDR-TB</keyword>
	<keyword>Multi-drug resistant</keyword>
	<keyword>Extensively drug resistant</keyword>
	<keyword>Bedaquiline</keyword>
	<keyword>PA-824</keyword>
	<keyword>Linezolid</keyword>
	<keyword>TB</keyword>
	<keyword>Pretomanid</keyword>
	<keyword>TMC-207</keyword>
	<keyword>NiX-TB</keyword>
</DOC>